BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
BRCA1 Protein
/ genetics
BRCA2 Protein
/ genetics
Breast Neoplasms
/ drug therapy
Carcinogenesis
/ genetics
Cell Proliferation
/ drug effects
Drug Resistance, Neoplasm
/ drug effects
Female
Genomic Instability
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Mutation
Ovarian Neoplasms
/ drug therapy
Poly(ADP-ribose) Polymerase Inhibitors
/ pharmacology
Prognosis
Progression-Free Survival
Protein Kinase Inhibitors
/ therapeutic use
Recombinational DNA Repair
/ drug effects
Signal Transduction
/ drug effects
HRD
HRP
PARP
PARP inhibitor
homologous recombination
homologous recombination deficient
homologous recombination proficient
immunotherapy
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
pubmed:
2
6
2021
medline:
15
12
2021
entrez:
1
6
2021
Statut:
ppublish
Résumé
Patients who have mutations of the genes
Identifiants
pubmed: 34058833
doi: 10.2217/fon-2021-0072
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Immune Checkpoint Inhibitors
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM